Filter your results
- 2
- 1
- 3
- 3
- 1
- 1
- 1
- 3
- 3
- 3
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Assessment of DOAC in GEriatrics (ADAGE study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patientsThrombosis and Haemostasis, In press, ⟨10.1055/a-1981-1763⟩
Journal articles
hal-03892903v1
|
||
|
Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulantsThrombosis Research, 2019, 184, pp.86-91. ⟨10.1016/j.thromres.2019.11.001⟩
Journal articles
hal-02397750v1
|
||
|
Are Screening Tests Reliable to Rule Out Direct Oral Anticoagulant Plasma Levels at Various Thresholds (30, 50, or 100 ng/mL) in Emergency Situations?Chest, 2018, 153 (1), pp.288-290. ⟨10.1016/j.chest.2017.09.047⟩
Journal articles
hal-03892975v1
|